Dear Colleagues & Friends,

It was a great honor for us to host many of you from around the world in San Francisco for the 11th annual WuXi Global Forum on January 10th, 2023. The theme of this year’s forum was B.O.L.D. where we reflected on the state of innovation and highlighted our industry’s notable advances in tackling innovation challenges to build an impactful future for patients: Breaking Barriers, Opening New Horizons, Leading Next Generation, and Delivering on the promise for patients.

To our esteemed guest speakers, THANK YOU for leading the way with new thinking and actionable approaches as we work together to shape the future of healthcare.

Special thanks to our supportive partners: A*STAR, BioCentury, Biocom California, BioWorld, California Life Sciences, Davos Alzheimer’s Collaborative, GEN, Medicon Valley Alliance, QB3, Swiss Biotech Association, UC Berkeley incubator Bakar Labs and UK BioIndustry Association.

Agenda

01:00 PM - 01:30 PM Onsite Check-in and Networking

01:30 PM - 01:35 PM Welcome

Hui Cai, Program Chair and Vice President, WuXi AppTec

01:35 PM - 01:45 PM Opening Remarks

Minzhang Chen, Co-CEO, WuXi AppTec

01:45 PM - 02:30 PM State of Innovation 2023

Todd Golub, Director, Broad Institute of MIT & Harvard

John Ngai, Director, NIH BRAIN Initiative

Vijay Pande, General Partner, Andreessen Horowitz

Aviv Regev, Head, Genentech Research and Early Development

Michael Severino, CEO, Tessera Therapeutics; CEO-Partner, Flagship Pioneering

Session Leader: Mathai Mammen, Executive Vice President of R&D, Johnson & Johnson Pharmaceuticals (in transition)

02:30 PM - 03:10 PM Breaking Barriers: Druggability Redefined

Ros Deegan, CEO, OMass Therapeutics

Dan Nomura, Professor of Chemical Biology and Molecular Therapeutics, University of California, Berkeley

Nancy Pryer, CSO, Ambagon Therapeutics

Lance Stewart, Chief Strategy and Operations Officer, Institute for Protein Design, University of Washington

Session Leader: C. Simone Fishburn, VP & Editor in Chief, BioCentury Inc.

03:10 PM - 03:50 PM Opening New Horizons: Spotlight on RNA Therapeutics

Tom Barnes, CEO, Orna Therapeutics

John Mendlein, Chairman, Laronde; Executive Partner, Flagship Pioneering

Romesh Subramanian, CEO, Ascidian Therapeutics

Michelle Werner, CEO, Alltrna; CEO-Partner, Flagship Pioneering

Session Leader: Nina Kjellson, General Partner, Canaan

03:50 PM - 04:30 PM Leading Next Generation of Cell and Gene Therapies

Ken Drazan, Chairman, CEO, Co-Founder, ArsenalBio

Keith Gottesdiener, President & CEO, Prime Medicine

Laura Shawver, President & CEO, Capstan Therapeutics

Catherine Stehman-Breen, CEO, Chroma Medicine

Session Leader: Edward Hu, Vice Chairman, Global Chief Investment Officer, WuXi AppTec

04:30 PM - 05:05 PM Delivering on the Promise for Patients

Giulio Draetta, SVP & CSO, MD Anderson Cancer Center

Stephen Hauser, Director, UCSF Weill Institute for Neurosciences; Professor, Department of Neurology, University of California, San Francisco

Joseph Wu, Director of Stanford Cardiovascular Institute; President-Elect of American Heart Association

Session Leader: Christiana Bardon, Co-Managing Partner of BioImpact Capital, an MPM affiliate

05:05 PM - 05:50 PM Building an Impactful Future

Niranjan Bose, Managing Director, Health & Life Sciences, Gates Ventures

Juergen Eckhardt, SVP & Head of Leaps by Bayer

Sofia Ioannidou, Partner, Andera Partners

Carol Suh, Partner, ARCH Venture Partners

Sze-Wee Tan, Assistant Chief Executive, Innovation and Enterprise Group, Singapore Agency for Science, Technology and Research (A*STAR)

Session Leader: Michal Preminger, Regional Head, Johnson & Johnson Innovation East North America

05:50 PM - 06:00 PM Closing Remarks

Steve Yang, Co-CEO, WuXi AppTec

06:00 PM - 07:00 PM Networking Reception